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A multicomponent nutrient bar promotes weight loss and
improves dyslipidemia and insulin resistance in the
overweight/obese: chronic inﬂammation blunts
these improvements
Joyce C. McCann,*,1 Mark K. Shigenaga,*,1 Michele L. Mietus-Snyder,*,† Ashutosh Lal,*
Jung H. Suh,* Ronald M. Krauss,* Ginny L. Gildengorin,* Alisa M. Goldrich,* Devan S. Block,*
Swapna V. Shenvi,* Tara H. McHugh,‡ Don A. Olson,‡ and Bruce N. Ames*
*Nutrition and Metabolism Center, Children’s Hospital Oakland Research Institute, Oakland, California,
USA; †Children’s National Medical Center, Washington, DC, USA; and ‡Processed Foods Research Unit,
U.S. Department of Agriculture-Agricultural Research Service-Western Regional Research Center,
Albany, California, USA
This study determined if twice-daily consumption of a nutrient-dense bar intended to ﬁll gaps in
Western diets, without other dietary/lifestyle requirements, favorably shifted metabolic/anthropometric indicators of dysregulation in a healthy direction. Three 8-wk
clinical trials in 43 healthy lean and overweight/obese
(OW/OB) adults, who served as their own controls, were
pooled for analysis. In less inﬂamed OW/OB [highsensitivity C-reactive protein (hsCRP) <1.5], statistically
signiﬁcant decreases occurred in weight (21.1 6 0.5 kg),
waist circumference (23.1 6 1.4 cm), diastolic blood
pressure (24.1 6 1.6 mmHg), heart rate [HR; 24.0 6 1.7
beats per minute (bpm)], triglycerides (272 6 38.2 mg/dl),
insulin resistance (homeostatic model of insulin resistance) (20.72 6 0.3), and insulin (22.8 6 1.3 mU/L);
an increase in HDL-2b (+303 6 116 nM) and realignment
of LDL lipid subfractions toward a less atherogenic proﬁle
[decreased small LDL IIIb (244 6 23.5 nM), LDL IIIa
(299 6 43.7 nM), and increased large LDL I (+66 6 28.0 nM)].
In the more inﬂamed OW/OB (hsCRP >1.5), inﬂammation was reduced at 2 wk (20.66 mg/L), and HR at
8 wk (23.4 6 1.3 bpm). The large HDL subfraction
(10.5–14.5 nm) increased at 8 wk (+346 6 126 nM). Metabolic improvements were also observed in lean participants.
Thus, favorable changes in measures of cardiovascular
health, insulin resistance, inﬂammation, and obesity were
initiated within 8 wk in the OW/OB by replacing deﬁciencies in Western diets without requiring other dietary or lifestyle modiﬁcations; chronic inﬂammation
blunted most improvements.—McCann, J. C., Shigenaga,
M. K., Mietus-Snyder, M. L., Lal, A., Suh, J. H., Krauss,
R. M., Gildengorin, G. L., Goldrich, A. M., Block, D. S.,
ABSTRACT

Abbreviations: aka, also known as; BMI, body mass index;
BP, blood pressure; bpm, beats per minute; CVD, cardiovascular disease; DBP, diastolic blood pressure; DHA, docosahexaenoic acid; HDL-L, large HDL subfraction; HDLPs, total
HDL subfractions; HOMA-IR, homeostatic model of insulin resistance; HPMC, hydroxypropylmethylcellulose; HR, heart rate;
(continued on next page)
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OVERCONSUMPTION OF WESTERN DIETS HIGH in calories, sugar,
salt, and unhealthy fats, but low in micronutrients [many
essential vitamins and minerals (Vs/Ms) and v-3 fatty
acids], ﬁber, and plant polyphenolics (1–4), is a major
cause of the increasing prevalence of obesity worldwide
(5–7). Such diets directly contribute to the metabolic dysregulation that usually accompanies obesity (8–11) and is
also present in ;25% of lean individuals (12, 13). Metabolic
dysregulation includes chronic inﬂammation, insulin resistance, dyslipidemia, and oxidative stress (14, 15). Several
metabolic abnormalities, together with visceral adiposity
and high blood pressure (BP), are collectively termed “the
metabolic syndrome” (11, 16). Various aspects of metabolic
dysregulation have been shown to be independent risk
factors for cardiovascular disease (CVD) and type 2 diabetes,
and putative risk factors for the many other obesityassociated diseases including cancer, autoimmune disorders, asthma, and neurodegenerative conditions (17–22).
Because poor diets are a root cause of these health
problems, an obvious approach to the obesity epidemic
would be to improve dietary habits. However, changing
dietary patterns is difﬁcult for many people to initiate and
sustain (23–25).
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We have developed, guided by 18 small clinical trials
conducted over the last 10 years, a low-calorie, fruit-based
bar fortiﬁed with micronutrients, ﬁber, and other dietary
components inadequate in a typical Western diet (26).
This approach was based on the hypothesis that metabolic
dysregulation common in the obese (with consequent increased disease risk) is due in large part to what is missing
or inadequate in Western diets, and might be improved by
increasing intake of these food components.
In addition to the bar having practical application as
a nutritional supplement to attenuate the adverse metabolic impact of obesity and hopefully encouraging transition to healthier eating habits, a major goal was to use the
nutrient mixture as a scientiﬁc tool to investigate mechanisms by which individual dietary components in a complex
dietary mixture interact with each other and with human
metabolism. Because the composition of the bar is deﬁned
and easily manipulated, deconstruction studies aimed at
understanding mechanisms are quite feasible, whereas this
type of mechanistic detective work would be virtually impossible to do in human trials with a complete diet.
A great deal of evidence points to the impact of dietary
deﬁciencies on metabolic health. For example, low intake
of fruits, vegetables, and ﬁsh by the great majority of the
population in the United States (1, 27), with consequent
inadequate intake of many essential V/Ms (28), results in
low V/M status, which is particularly apparent in obese
people (29–33). Triage theory (34–37) provides a mechanistic rationale for why essential V/M inadequacies common in Western diets increase future chronic disease risk.
Research also links other dietary deﬁciencies common in
typical Western diets to increased risk for chronic disease or
metabolic dysregulation. Examples include low intake of
dietary ﬁber (38–40) and its fermentation products [shortchain fatty acids (41, 42) and glutamine (43–45)], plant
polyphenolics (46–49) and v-3 fatty acids (50).
Throughout development of the nutrient mixture, formulation modiﬁcations to improve palatability and efﬁcacy
were guided by small clinical trials that examined effects
of formulation modiﬁcations on a range of clinical biochemical and anthropometric measures [(51); unpublished
results]. A simple and economical experimental design was
used for these trials. Participants acted as their own control
subjects and were not asked to modify their existing diets
during the course of the trial, consistent with our hypothesis
that adding back inadequate dietary components would be
sufﬁcient to result in positive change. For further discussion on development of the nutrient bar, see our earlier
paper (51).
Background/rationale for the current report
Early clinical trials were of short duration (2 wk) and included healthy, predominantly lean, or only slightly overweight adults. Our previous report (51) indicated that
twice-daily consumption of the nutrient bar for 2 wk
(continued from previous page)
hsCRP, high-sensitivity C-reactive protein; IDL, intermediatedensity lipoprotein; OW/OB, overweight/obese; PPAR, peroxisome proliferator-activated receptor; RCT, reverse cholesterol
transport; SAA, serum amyloid A; TC, total cholesterol; TG,
triglyceride; V/M, vitamins and minerals
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resulted in a striking increase in most participants in HDLcholesterol (HDL-c), particularly the large HDL subfraction [designated HDL-L or HDL-2b (10.5–14.5 nm)].
HDL-2b is generally considered to be associated with less
future CVD risk (52, 53) and may reﬂect increased reverse
cholesterol transport (RCT), an antiatherogenic function
of HDL (54).
Subsequent trials included both 2 wk and 2 month time
points and approximately equal numbers of lean and
overweight/obese (OW/OB) adults. This report presents
results of 3 of these 2 month trials using bars of comparable
ﬁber and nutrient composition. The major goal of the
analysis was to test whether bar consumption without other
lifestyle modiﬁcations could shift metabolic dysregulation
in the OW/OB toward a “leaner” proﬁle, and to conﬁrm,
and extend to 2 months, results of earlier 2 wk trials in
predominantly lean individuals (51). Plasma concentrations of standard clinical metabolic and anthropometric
measures, lipid protein subfractions, the adipokine adiponectin (55), and the acute phase protein serum amyloid
A (SAA) (56) were quantiﬁed at baseline, and after 2 and
8 wk of twice-daily consumption of the nutrient bar.

MATERIALS AND METHODS
Composition of the nutrient bars
The nutrient bars used in this study were similar to the prototype bar
described previously (51). The major difference in the bars utilized
in this study compared to the prototype bar (51) is the substitution
of half of the soluble ﬁber with hydroxypropylmethylcellulose
(HPMC), a highly viscous, nonfermentable soluble ﬁber (57).
Bars used in the 3 trials presented here were identical except in
amounts of some vitamins (vitamins A, D3, and K1 and folate) and
some fruits with high polyphenol (anthocyanin) content, though
these differences did not affect outcome distributions (see “Statistical analysis”). Each trial used a different bar. Nutrient proﬁles
of the 3 bars are in Table 1.
Study cohort
A total of 43 generally healthy adults participated in $1 of 3
identical 2-month trials conducted over a period of 4 years. There
were 10 participants in 2 trials; 5 were in 3 trials. Each trial was
separated by .1 year. There were 2 participants excluded from
the analysis because their baseline fasting blood glucose was
.126 mg/dl, indicating diabetes. One participant was excluded
from analysis because high-sensitivity C-reactive protein (hsCRP)
values for all 3 time points were .10 mg/L, indicating probable
infection (60). There were 4 individual hsCRP data points .10
(in 4 participants) also excluded. All but one of these high values
were supported by documentation of either a cold or allergy at the
time of the clinical research center visit. Data points corresponding to these 4 excluded values were also removed for all
non-hsCRP parameters analyzed. A single outlier baseline value
was also removed from the SAA data set that was 5 SDs greater than
the mean. The trials were identical in design and involved twicedaily intake of the nutrient bar. Characteristics of the study cohort
are shown in Table 2. Exclusion criteria were intercurrent infectious disease, untreated stage II hypertension, and medication
for diabetes or dyslipidemia. Clinical trials were approved by the
institutional review board of Children’s Hospital and Research
Center Oakland. All participants signed informed consent forms
prior to enrollment.
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TABLE 1. Composition of bars
Bar components

Total calories (kcal)
Total fat (g)
Saturated fat (g)
Trans fat (g)
Cholesterol (mg)
DHA, 22:6 n-3 (mg)
Sodium (mg)
Potassium (mg)
Total carbohydrate (g)
Fiber, total dietary (g)
Sugars (g)
Total protein (g)
Vitamin A (retinol activity
equivalents)
b-Carotene (mg)
Calcium (mg)
Vitamin D3 (IU)
Vitamin K1 (mg)
Riboﬂavin (mg)
Vitamin B6 (mg)
Vitamin B12 (mg)
Pantothenic acid (mg)
Zinc (mg)
Copper (mg)
Chromium (mg)
Vitamin C (mg)
Iron (mg)
Vitamin E (a, g tocopherols) (mg)
Thiamine (vitamin B1) (mg)
Niacin (mg)
Folate (mg)
Biotin (mg)
Phosphorus (mg)
Magnesium (mg)
Selenium (mg)
Manganese (mg)
Choline (mg)
Glutamine (g)
Lactate (mg)
Glycerine (g)
Total polyphenols (mg)
Monomeric polyphenols (mg)

Bar 1

Bar 2

Bar 3

107
5.04
2.52
0.0
0.0
200
2.71
142
19.7
7.31
7.58
3.78
71.9

124
5.09
2.54
0.0
0.0
200
3.002
158
25.4
8.79
11.0
3.91
35.6

107
5.04
2.52
0.0
0.0
200
2.71
142
19.7
7.31
7.58
3.78
71.9

201
287
0.0
45
0.63
0.69
0.80
1.39
2.8
283
33
105
1.89
6.63
0.43
7.77
316
7.5
42.2
179
6.24
0.36
127
1.0
0.0
1.00
473
87.8

180
362
2300
36
0.65
0.71
0.80
1.35
2.84
287
33
106
1.98
6.70
0.44
7.90
558
7.5
45.1
180
6.20
0.36
128
1.0
326
1.50
515
157

201
287
200
45
0.63
0.69
0.80
1.39
2.8
283
33
105
1.89
6.63
0.43
7.77
316
7.5
42.2
179
6.24
0.36
127
1.0
0.0
1.00
473
87.8

Values are amounts contained in 1 bar; dosage is 2 bars per day. Values were calculated from U.S.
Department of Agriculture (USDA) tables (58) and individually added nutrients. Fruit concentrate
polyphenol concentrations are derived from the USDA Database for the Flavonoid Content of Selected
Foods, Release 2.1 (59). The Nutrient Database numbers are 09050, 09078, 97074, and 09279. Polyphenol
content of blueberry powder was provided by the Highbush Blueberry Council. The patent is pending (26).

Intervention
The study design was an open label, nonrandomized 8 wk clinical
trial in which participants acted as their own control subjects.
Participants were advised to discontinue all vitamin, mineral, and
ﬁber supplements and any other nutraceuticals 2 wk before the
initiation of each trial. Compliance with these guidelines as well as
absence of intercurrent infectious disease was assessed by selfreport. Consumption of 2 bars each day was advised, with the ﬁrst
to be eaten before noon and the second in either the afternoon or
evening. Participants were advised to drink a minimum of 8
ounces of water with each bar. No guidelines as to whether to use
the bar as a meal replacement or a supplement were given.
Baseline, 2 and 8 wk visits to the clinical research center included measurements of height, weight, and waist circumference
taken at the umbilicus. Compliance with bar consumption

NUTRIENT BAR IMPROVES METABOLISM AND WEIGHT LOSS

averaged 95%, as assessed by questionnaire at each visit to the
clinical research center. Each physical measurement was taken
twice and averaged. BP and heart rate (HR; Dinamap, GE
Healthcare, Wauwatosa, WI, USA) were assessed in triplicate and
averaged. Fasting venous blood samples were taken in EDTAcontaining tubes and immediately processed.
Biochemical analyses
Lipid proﬁles
Plasma samples prepared within 15 min of collection were kept at
4°C throughout processing. For 1 of the 3 trials analyzed, the basic
lipid panel [total cholesterol (TC), triglycerides (TGs), HDL-c,
and LDL cholesterol (LDL-c)] was determined as follows. Plasma
TC and TG concentrations were determined by enzymatic
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TABLE 2. Baseline metabolic and anthropometric characteristics of OW/OB and lean participants
Characteristics

Mean clinical measures (SD)
Age (years)*
Female sex (%)a
Physical
BMI*
Weight (kg)*
Waist circumference (cm)*
Systolic BP (mmHg)*
Diastolic BP (mmHg)*
HR (bpm)
Lipids
HDL-c (mg/dl)*
LDL-c (mg/dl)†
TC (mg/dl)
Non-HDL-c (mg/dl)*
TGs (mg/dl)*
VLDL-c (mg/dl)*
TG/HDL-c*
Insulin resistance
Glucose (mg/dl)*
Insulin (mU/L)*
HOMA-IR*
Inﬂammation related
hsCRP(mg/L)*
Adiponectin (ng/ml)*
SAA (ng/ml)
Mean lipoprotein particle measurements (SD)
HDL particles
HDL-2b (nM)*
HDL3_2a (nM)
Total (nM)†
LDL particles
Peak diameter (Å)*
LDL I (nM)
LDL IIa (nM)†
LDL IIb (nM)*
LDL IIIa (nM)†
LDL IIIb (nM)
LDL IVa (nM)
LDL IVb (nM)
LDL IVc (nM)
Total (nM)*
VLDL and IDL particles
IDL I (nM)
IDL II (nM)†
VLDL small (nM)
VLDL intermediate (nM)*
VLDL large (nM)*

BMI ,25

BMI $25

(n = 29)
43.4 (14.3)
86.7

(n = 30)
52.7 (12.6)
40

22.6
62.3
80.5
112.2
70.7
64.7

(1.7)
(8.4)
(6.5)
(11.0)
(7.5)
(11.9)

29.7
92.0
104.0
120.8
77.8
67.0

(3.4)
(16.8)
(11.5)
(9.7)
(8.3)
(6.9)

68.7
101.3
186.1
115.0
80.7
16.1
1.4

(20.8)
(34.0)
(35.6)
(37.9)
(41.2)
(8.2)
(1.2)

49.8
124.4
201.9
149.2
157.4
31.5
3.9

(12.5)
(36.6)
(36.6)
(36.6)
(118.9)
(23.8)
(4.7)

93.3 (7.7)
6.4 (3.9)
1.4 (0.8)

102.8 (7.5)
13.3 (6.9)
3.4 (1.7)

0.87 (1.3)
6797 (5895)
918.4 (667.7)

2.1 (1.6)
3179 (2858)
3887 (8526)

(n = 28)

(n = 30)

3187 (1959)
5548 (1788)
8736 (2704)

1467 (967.1)
5686 (1391)
7152 (1747)

224.7 (6.1)
346.3 (128.3)
210.0 (98.1)
205.2 (103.1)
147.7 (121.3)
52.5 (48.0)
57.3 (30.9)
52.6 (23.3)
32.8 (10.2)
1105 (354.4)

219.8
346.0
267.2
297.2
248.2
88.4
76.0
65.9
37.0
1426

(6.2)
(145.6)
(92.4)
(110.9)
(172.0)
(82.7)
(48.1)
(26.9)
(15.1)
(313.8)

170.8 (65.3)
277.7 (131.7)
72.7 (31.9)
49.6 (26.6)
15.0 (12.3)

188.3
204.8
72.7
65.8
25.7

(58.5)
(76.4)
(24.6)
(24.1)
(14.5)

n refers to the number of observations measured, not the number of participants (see Materials
and Methods). The number of observations averaged for each measure is indicated at the head of each
column unless otherwise indicated. BMI ,25: n = 23 (non-HDL), n = 27 (adiponectin), and n = 5 (SAA).
BMI $25: n = 28 (LDL-c), n = 22 (non-HDL), n = 30 (adiponectin), and n = 18 (SAA). The differences in
this table are not intended to represent a deﬁnitive comparison because the lean and OW/OB groups
were not matched for age, sex, or ethnicity, which are known to affect the metabolic proﬁle. Ethnicities
were BMI ,25 (48% Caucasian, 31% Asian-American, 7% Hispanic, 7% unknown, 3% African American,
and 3% other) and BMI $25 (58% Caucasian, 10% Asian-American, 16% Hispanic, 10% unknown, and
6% African American). HDL3_2a, small HDL (7.6–10.5 nm). For HDL, LDL, and other particle
deﬁnitions, see Abbreviations. aNo signiﬁcant difference by x2 analysis. *P , 0.01; †P , 0.05.

procedures on an Express 550 Plus analyzer (Ciba Corning,
Oberlin, OH, USA) controlled by the U.S. Centers for Disease
Control and Prevention-U.S. National Institutes of Health
National Heart, Lung, and Blood Institute standardization monitoring program. HDL-c was measured after dextran sulfate
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precipitation of plasma. LDL-c was calculated using a standard
formula (61) for all samples with TG concentrations ,400 mg/dl.
For the other 2 trials analyzed, the basic lipid panel (TC, TGs,
HDL-c, and LDL-c) was determined by a commercial provider
(ARUP Laboratories, Salt Lake City, UT, USA). Ion mobility
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analysis was used to measure concentrations of lipoprotein subfractions in all 3 trials, as previously described (62).
Other measures
Plasma fasting glucose, insulin, and hsCRP were measured using
standard procedures by a commercial provider (ARUP Laboratories). Insulin resistance was estimated using the homeostatic
model of insulin resistance (HOMA-IR) calculated as fasting
glucose (milligrams per deciliter) 3 fasting insulin (milli-international
units per liter) 4 405. High molecular weight adiponectin was
measured by solid-phase sandwich ELISA (Quantikine; R&D
Systems, Minneapolis, MN, USA). SAA was measured using detection antibodies that emit light upon electrochemical stimulation (Meso Scale Discovery, Rockville, MD, USA).
Statistical analysis
Prior to pooling data from the 3 trials, quantitative measures and
changes from baseline to 2 and 8 wk were assessed by ANOVA within
each trial. Outcome distributions were similar in all 3 trials, and
results were pooled. All statistical analyses were performed using
SAS (version 9.3; SAS Institute, Cary, NC, USA). Variables included
standard clinical metabolic and anthropometric measures and lipoprotein subfraction concentrations. Means 6 SE were calculated
for the various subgroups and time points. Correlations were computed using Spearman’s nonparametric estimates. Data were examined for assumptions of normality using measures of skewness
and kurtosis, plots, and the Anderson-Darling test. Log transformations were performed for highly skewed data (HOMA-IR, insulin, hsCRP, TGs, SAA, and adiponectin). Initial bivariate analysis
using Student’s t test was conducted to compare baseline values
between lean and OW/OB. Linear regression models were constructed on the continuous outcomes and on changes from baseline. Bar-induced changes were examined over time in the OW/OB
and in the 2 OW/OB subgroups using general linear models with
time treated as repeated measures. The generalized estimating
equation approach, with an exchangeable working correlation
structure, was used to account for the within-person correlation in
outcomes at different time points (i.e., statistical analysis included
adjustment for participants who were in .1 trial). A signiﬁcance
level of 0.05 was used for all statistical tests. Because multiple statistical tests were conducted, some false positives may have occurred.

OW/OB and lean participants, concentrations of small
LDL subfractions are strongly and positively correlated
with TG concentration and strongly and negatively correlated with HDL-c. The correlation coefﬁcient of the sum of
the 2 most atherogenic small subfractions (LDL IIb and
IIIa) (72) with HDL-c is 20.74 (P , 0.001; n = 60) and with
TGs is +0.71 (P , 0.001; n = 60).
Effects of 2 and 8 wk twice-daily consumption of 2
nutrient bars in lean and OW/OB healthy adults
Effects of nutrient bar consumption in the lean
Previously, we reported that consumption of 2 nutrient
bars a day for 2 wk by healthy, predominantly lean [body
mass index (BMI) ,25] or slightly overweight adults signiﬁcantly increased HDL-c, particularly the HDL-2b [also
known as (aka) HDL-L] (51). Similar results were observed
at 2 wk for lean participants in this study and persisted at
8 wk, as shown in Fig. 1. HDL-c increased in 76% of participants, with an overall average increase of 4.1 6 1.0 mg/dl
(P , 0.001), and HDL-2b increased 492 6 148 nM (P , 0.007).
The additional major change observed in this study was
a large increase in the adipokine adiponectin, not measured in our earlier study (51), which also increased very
signiﬁcantly at 2 wk (+1026 6 405 ng/ml; P , 0.002) and
8 wk (+1475 ng/ml; P = 0.005).
Additional parameters for which changes were statistically signiﬁcant at 8 wk included total HDL subfractions (HDLPs) (+859 6 296 nM; P = 0.0040) and TC
(+9.5 6 3.2 mg/dl; P = 0.0029), not unexpected given
the robust increases in HDL measures, and several
other statistically signiﬁcant changes: non-HDL cholesterol (+6.6 6 3.1 mg/dl; P = 0.044), waist circumference
(+1.1 6 0.6 cm; P = 0.042), and LDL IIa (+20.4 6 9.2 nM;
P = 0.047). There were no statistically signiﬁcant changes

RESULTS
Baseline characteristics of lean and OW/OB
participants
Baseline metabolic characteristics of lean and OW/OB
participants are shown in Table 2 and reﬂect recognized
differences between these groups (63–68). As shown,
HDL-c is signiﬁcantly lower in the OW/OB, and BP, LDL-c,
TGs, insulin resistance (as measured by HOMA-IR), insulin, glucose, and inﬂammation (as measured by hsCRP)
are all signiﬁcantly higher. Adiponectin and SAA also reﬂect known differences between the OW/OB and lean.
Adiponectin is signiﬁcantly higher in the lean (55, 69), and
SAA is higher in the OW/OB (70).
Signiﬁcant lipoprotein subfraction differences between
the OW/OB and lean groups are 1) higher concentrations
of HDL-2b and intermediate-density lipoprotein (IDL) II
in the lean, 2) greater LDL peak diameter in the lean, and
3) lower concentrations of LDL IIb and large VLDL (very
LDL) in the lean. In addition, as expected (71), across all
NUTRIENT BAR IMPROVES METABOLISM AND WEIGHT LOSS

Figure 1. Effects of the nutrient bar in the lean (BMI ,25)
after 2 and 8 wk consumption of 2 nutrient bars each day.
Chol., cholesterol; Circum., circumference. Values plotted are
changes from baseline, averaged across all participants and
plotted as percentage of the overall baseline mean for each
endpoint. Average changes and SE are speciﬁed below the
ﬁgure. HDL-2b is one of the 2 classes of HDL subfractions
identiﬁed by the lipid particle-sizing assay and is deﬁned in
Abbreviations. *P , 0.05; **P , 0.01; tP , 0.10.
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in any other biochemical or anthropometric measures at
8 wk in the lean group (data not shown).

Effects in the OW/OB
Bar-induced changes after 2 and 8 wk in the OW/OB are
shown for metabolic (Fig. 2A) and anthropometric (Fig.
2B) measures and in Fig. 3 for lipid subfractions. As shown,
after 8 wk consumption of 2 bars a day, statistically signiﬁcant (P , 0.05) or trending signiﬁcant (P , 0.10) changes
in the direction of baseline values typical of the lean
(Table 2) were observed: HDL-c (+2.4 6 1.2 mg/dl;
P = 0.078); TGs (234.3 6 21.0 mg/dl; P = 0.061); insulin
resistance (as measured by HOMA-IR, 20.60 6 0.2;
P = 0.011); insulin (22.3 6 0.90 mU/L; P = 0.0088);
glucose (22.2 6 1.2 mg/dl; P = 0.054); and adiponectin
(+743 6 431 ng/ml; P = 0.079) (Fig. 2A). Changes in hsCRP
(20.30 6 0.22 mg/L) and SAA (2204 6 236 ng/ml) were
also in the direction of improvement. Improvements in
anthropometric measures were also observed, as shown in
Fig. 2B: diastolic blood pressure (DBP) (22.4 6 1.3 mmHg;
P = 0.082); HR [23.7 6 1.0 beats per minute (bpm);
P , 0.001]; weight (20.80 6 0.40 kg; P = 0.039); and waist
circumference (21.80 6 0.90 cm; P = 0.043).
Changes in lipid subfractions are shown in Fig. 3.
Changes in HDL subfractions (HDL-2b and HDL3_2a)
indicate that nutrient bar-induced increase in HDL-c in the
OW/OB is primarily due to an increase in the HDL-2b (aka
HDL-L), as reported previously in predominantly lean
individuals (51).
Little change in LDL-c is apparent in Fig. 2A. However,
examination of Fig. 3 suggests consistent favorable
decreases across the more atherogenic (72) small LDL
subfractions (LDL IVa, IVb, and IVc and LDL IIIa and
IIIb) and consistent favorable increases in the less atherogenic (72) larger subfractions (LDL I and IIa and
IDL 2). Only increases in 2 large subfractions [LDL I
(+40.8 6 18.1 nM) and IDL 2 (+20.7 6 10.5 nM)] reached
statistical signiﬁcance, and decreases in only 2 small

subfractions trended signiﬁcant [LDL IIIb (221.7 6 12.4 nM;
P = 0.069) and IIIa (244.0 6 24.7 nM; P = 0.077)]. However,
the consistency of downward movement in the small
dense subfractions and upward movement in the larger
subfractions is persuasive.
In summary, consumption of 2 bars each day for
2 months resulted in positive changes in indicators of cardiovascular health (HDL and LDL dyslipidemia, DBP, and
HR), insulin resistance (HOMA-IR, insulin, and glucose),
and obesity itself (weight and waist circumference). The
signiﬁcant increase in adiponectin is also consistent
with improved metabolic health (55, 69, 73). There were
no gastrointestinal or other adverse effects from bar
consumption.
Inﬂammation blunts responsiveness to
bar consumption
In the OW/OB, baseline inﬂammation (hsCRP) is inversely
correlated with early (2-wk) increase in all 4 HDL measures
and with later (8-wk) increase in less atherogenic LDL and
IDL lipid subfractions
As shown, baseline hsCRP in the OW/OB is inversely
correlated with bar-induced change from 0–2 wk (but not
0–8 wk) in all measures of HDL: HDL-c (r = 20.42;
P = 0.025); HDL3_2a (r = 20.47; P = 0.010); HDL-2b
(r = 20.44; P = 0.018); and HDLP (r = 20.55; P = 0.0021)
(Fig. 4A–D). Baseline hsCRP was also inversely correlated
with bar-induced 0–8 wk (but not 0–2 wk) change in the less
atherogenic LDL subfractions LDL I (r = 20.52; P = 0.0044)
and IDL 2 (r = 20.46; P = 0.015). No additional correlations
were observed.
In the OW/OB, improvement in almost all measures occurs
more robustly in those who are less inﬂamed at baseline
Baseline hsCRP values in OW/OB participants are illustrated in Fig. 5. As shown, approximately half of the

Figure 2. Improvements of measures linked to cardiovascular risk, insulin resistance, inﬂammation, and obesity in the OW/OB.
A) Metabolic. B) Anthropometric. Results after consumption of 2 nutrient bars per day for 2 and 8 wk are shown. *P , 0.05,
**P , 0.01, tP , 0.10. See Fig. 1 legend for additional information.
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Figure 3. Improvements of lipoprotein subfractions in the
OW/OB. HDL, LDL, IDL, and
VLDL subfractions are as deﬁned
in Abbreviations. intermed., intermediate. *P , 0.05, **P , 0.01,
t
P , 0.10. See Fig. 1 legend for
additional information.

baseline hsCRP values fall below an informal cutoff of 1.5,
which has been used to classify chronic inﬂammation
linked to CVD risk (74).
In Figs. 6, 7, and 8, effects of nutrient bar consumption
for 2 and 8 wk are shown for each of these 2 inﬂammation
subgroups for basic clinical measures (Figs. 6 and 7) and
lipoprotein subfractions (Fig. 8). All measures with
changes that were either statistically signiﬁcant or trended
signiﬁcant in either the lower- or higher-inﬂammation
subgroup are plotted. As shown in Figs. 6A and 7A, with the

exception of adiponectin, nutrient bar-induced change in
the less inﬂamed subgroup is clearly more robust compared to the more highly inﬂamed subgroup. As shown in
Figs. 6B and 7B, change in the anthropometric measures is
also more robust in the less inﬂamed subgroup, with the
exception of decreased HR. In Fig. 8, a similar pattern is
seen for the lipid subfractions. HDL-2b increases in both
subgroups, but the response is slower in the more inﬂamed
subgroup. The suggestive realignment of less and more
atherogenic LDL and IDL subfractions toward a healthier

Figure 4. Spearman correlations in the OW/OB between baseline hsCRP and change after consumption of 2 nutrient bars each
day for 2 wk [(A) HDL-c (milligrams per deciliter), (B) HDL-2b (nanomolar), (C) HDL3_2a (nanomolar), and (D) HDLP
(nanomolar)] or change after 8 wk [(E) LDL I (nanomolar), and (F) IDL 2 (nanomolar)]. Correlation coefﬁcients and P values
were r = 20.42 and P = 0.025 (HDL-c), r = 20.44 and P = 20.018 (HDL-2b), r = 20.47 and P = 0.010 (HDL3_2a), r = 20.55 and
P = 0.0021 (HDLP), r = 20.52 and P = 0.0044 (LDL I), and r = 20.46 and P = 0.015 (IDL 2).

NUTRIENT BAR IMPROVES METABOLISM AND WEIGHT LOSS

3293

Figure 5. Distribution of baseline hsCRP values
among OW/OB participants. Each of the 30
observations in the OW/OB is plotted as
baseline hsCRP (milligrams per liter). All participants with baseline hsCRP values ,1.5 mg/L
were classiﬁed as less inﬂamed, and those with
baseline values .1.5 mg/L were classiﬁed as
more inﬂamed.

proﬁle after 8 wk of nutrient bar consumption, as observed
in the OW/OB group as a whole (Fig. 3), is now clearly
shown to be due to bar-induced changes in the lessinﬂamed subgroup.
Most of the nonsigniﬁcant decrease in hsCRP in the
OW/OB group (Fig. 2A) occurred in the higherinﬂamed subgroup; decrease at 8 wk was statistically
signiﬁcant (20.78 6 0.37 mg/L; P = 0.03). Changes in
SAA were not signiﬁcant.
DISCUSSION
A nutrient-dense, high-ﬁber, fruit-based, low-calorie bar
intended to restore nutrient adequacy by ﬁlling gaps in
Western diets was used as a dietary intervention in three
2-month clinical trials in lean and OW/OB healthy adults
to examine effects of consuming 2 bars a day on metabolic
and anthropometric measures. Metabolic improvements
were seen in both lean and OW/OB participants. Striking
improvements occurred in the OW/OB (Figs. 2 and 3),
primarily in participants with relatively low levels of chronic
inﬂammation (Figs. 4, 5, 6, 7, and 8). These improvements were in major areas that characterize metabolic

dysregulation associated with obesity: HDL and LDL dyslipidemia, as well as other indicators of cardiovascular
health (HR and DBP) and insulin resistance (HOMA-IR).
Statistically signiﬁcant improvements in weight and waist
circumference also occurred primarily in the OW/OB
group with lower levels of chronic inﬂammation (Figs. 2B
and 6B). These reductions were small, not unexpected
given the relatively short duration of the intervention and
the fact that ;220 daily kilocalories were added in the form
of the nutrition bar without requirements to adjust baseline diet or otherwise change behavior.
This is the ﬁrst report of which we are aware that documents the resistance of OW/OB individuals with higher
levels of chronic inﬂammation to dietary-induced improvements in a wide range of metabolic and anthropometric indicators of obesity-associated dysregulation. The
adverse effect of chronic inﬂammation on diet-induced
improvements in some lipids was previously observed
(75–79), and one study reported that baseline plasma IL-6
concentrations were signiﬁcantly higher in individuals
more resistant to weight loss (80).
It is of interest that bar-induced improvements at 8 wk in
HDL-2b and the adipokine adiponectin appeared to be
relatively independent of inﬂammation, occurring in the

Figure 6. Changes in the lowerinﬂammation OW/OB subgroup
after 2 and 8 wk consumption of
the nutrient bar. A) Metabolic.
B) Anthropometric. Parameters
plotted were selected from those
with changes that were statistically
signiﬁcant or trending signiﬁcant in either of the 2 inﬂammation subgroups over the 8-wk
period. Additional signiﬁcant
or trending signiﬁcant changes
not plotted are as follows. BMI:
0–8 = 20.25, P = 0.086; TC:
0–8 = 24.93 mg/dl, P = 0.079;
TG/HDL-c: 0–8 = 21.35, P = 0.046;
and non-HDL cholesterol:
0–8 = 27.10 mg/dl, P = 0.062.
*P , 0.05, **P , 0.01, tP , 0.10.
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Figure 7. Changes in the
higher-inﬂammation OW/OB
subgroup after 2 and 8 wk consumption of the nutrient bar.
(A) Metabolic and (B) anthropometric measures. Parameters
plotted were selected from those
with changes that were statistically
signiﬁcant or trending signiﬁcant
in either of the 2 inﬂammation
subgroups over the 8-wk period.
The only additional change not
plotted was non-HDL cholesterol:
0–8 = +6.8 mg/dl; P = 0.075.
**P , 0.01, tP , 0.10.

lean (Fig. 1), in the OW/OB as a whole (Figs. 2A and 3),
and in both OW/OB inﬂammation subgroups (Figs. 6A,
7A, and 8). Higher plasma concentrations of adiponectin
have been suggested as an overall biomarker of metabolic
health (73) and have been linked to increased HDL-c and
decreased inﬂammation (55, 81). Adiponectin was reported to induce RCT (82, 83), which could help to explain
the bar-induced increase in HDL-2b (54) observed here
and previously (51).
Effects of the nutrient bar on inﬂammation
Inﬂammatory response is a recognized mechanism in the
pathogenesis of atherosclerosis and related risk for CVD
(18). Among several measures of inﬂammation (including
SAA), hsCRP is preferentially recommended for clinical
use in identifying individuals at risk (18). In the OW/OB,
both hsCRP and SAA appeared to decrease after bar consumption, but results did not reach statistical signiﬁcance
(Fig. 2A). However, there was a statistically signiﬁcant reduction in hsCRP (;20%; P = 0.030) among participants

who fell into CVD risk categories considered to be high
average or high (Fig. 5) (18). Although a causal role of the
nutrient bar in improving inﬂammation cannot be inferred
from these results, it is suggested that the initial effect of the
bar in the more inﬂamed OW/OB subgroup may be to
decrease inﬂammation, which would then allow positive
changes in metabolic dysregulation to manifest over a longer period than the 8-wk duration of this intervention. In
this regard, it is noted that HDL-2b increased after 2 wks of
bar consumption in the lower-inﬂammation groups (lean,
Fig. 1; lower-inﬂammation OW/OB subgroup, Fig. 8A), but
not until 8 wk in the higher-inﬂammation OW/OB subgroup (Fig. 8B).
Possible mechanisms
It is suggested that improvements in such a wide range of
metabolic and anthropometric measures in the OW/OB
(Figs. 2, 3, 6, and 8) may be the result of the restoration
of impaired underlying metabolic processes due to the
resupply by the nutrient bar of critical dietary components

Figure 8. Changes in the lower- and higher-inﬂammation OW/OB subgroups after 2- and 8-wk consumption of the nutrient bar.
A) Lower-inﬂammation subgroup. B) Higher-inﬂammation subgroup. Lipid particle subfractions are shown. Parameters plotted
were those with statistically signiﬁcant or trending signiﬁcant changes in either of the 2 subgroups over the 8-wk period. Int.,
intermediate; Lg., large; Diam., diameter. *P , 0.05, **P , 0.01, tP , 0.10.
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deﬁcient in Western diets. Mitochondrial stress and
impaired gut wall integrity are candidate underlying processes that may be improved by bar consumption. Both of
these conditions are common in the obese (84, 85), and
both are linked to poor diets (86, 87) and to insulin resistance and inﬂammation (88, 89). Bar-induced reduction
of mitochondrial stress and improved gut integrity would
be expected to have multiple beneﬁcial consequences
similar to the metabolic improvements observed in this
study. The restoration of an internal metabolic environment that manifests a leaner metabolic proﬁle would also
allow the metabolic ﬂexibility required for weight loss and
clearance of ectopic adiposity (90, 91).
Mitochondrial stress
The metabolic efﬁciency of mitochondria in converting
fuel (carbohydrates, lipids, and amino acids) to ATP
decreases in the obese relative to the lean (92). The generation of oxidants is a consequence of the accumulation
of NADH over NAD+, which occurs due to chronic hyperglycemia resulting from overnutrition (93–95). Oxidants
directly interfere with insulin-signaling efﬁciency (96–98),
and oxidant-initiated oxidative damage triggers inﬂammation because cells that sustained such injury are cleared
by immune cells (98). Fatty acid accumulation resulting
from decreased mitochondrial efﬁciency also inhibits
insulin-signaling efﬁciency (99, 100).
There are several ingredients in the nutrient bar that
may positively impact mitochondrial stress. High-viscosity
dietary ﬁber HPMC has been shown to slow glucose absorption (101) and to preserve respiratory quotients in rats
consuming a high-fat diet (102). Furthermore, 2 nutrient
bars (the daily dose) also contain 400 mg docosahexaenoic
acid (DHA), a known peroxisome proliferator-activated
receptor (PPAR)-a agonist. Activation of the PPAR pathway leads to increased fatty acid oxidation and preferentially reduces small proatherogenic LDL subfractions
(103). The bar also contains high concentrations of polyphenolic compounds from fruit and dark chocolate.
Polyphenolic consumption in healthy overweight individuals has been shown to increase resting energy expenditure, which would relieve mitochondrial reductive stress
described above (104). Polyphenols also increase cellular
antioxidant defense by activating Nrf2 phase-2 detoxiﬁcation pathways that antagonize inﬂammation (105).
Gut wall integrity
Gut wall integrity and the intestinal microbiome are impaired by high-fat and high-sugar diets commonly consumed by the obese (106–108). Evidence points to the
importance of ﬁber, its metabolites, and other dietary
components (106, 109–111) in maintaining a healthy gut
barrier (112, 113) and intestinal microbiome (114) to
prevent diet-induced chronic inﬂammation and insulin
resistance (84, 106, 115). The consequence of poor nutrition is a condition termed “leaky gut,” in which fragments
of gram-negative bacteria (LPS aka endotoxin) pass
through the gut into systemic circulation, leading to
chronic inﬂammation (106, 116, 117). The nutrient bar
may help to strengthen the gut barrier epithelium through
3296
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provision of nutrients that support the gut’s bioenergetic
capacity and thus its resiliency to intestinal permeability
(118). These nutrients include soluble ﬁber and its fermentation products (26, 51) such as short-chain fatty acids
(41, 42), glutamine (43–45), and zinc (119–121). Such barinduced strengthening of the gut epithelium, and consequent reduction in plasma endotoxin, should be possible
within the ﬁrst 2 wk of bar consumption (122), compatible
with the observed early (2 wk) rise in HDL-2b and adiponectin. Decreasing endotoxin entry by strengthening the
gut wall would result in a reduction in inﬂammation
(106, 123) and the consequent endocrine (i.e., insulin and
leptin) (124, 125) and mitochondrial stress responses to
inﬂammation that make it difﬁcult to lose excess fat and
maintain a healthy body weight.

Summary
It is suggested that the less inﬂamed OW/OB subgroup is
less metabolically impaired and thus better poised to move
toward a leaner metabolic proﬁle in response to improved
function resulting from nutrients supplied by the bar.
The higher-inﬂammation subgroup must ﬁrst reduce inﬂammation. It is posited that reductions in hsCRP (Fig. 2),
most of which occurred in the higher-inﬂammation subgroup, may reﬂect what is potentially the ﬁrst step toward
a leaner metabolic proﬁle, which may require a longer
period to develop in more chronically inﬂamed individuals
than the 8-wk period of the trials analyzed in this report.
Practical implications for weight
management programs
Conventional weight management strategies can be successful [e.g., (126–128)], but results are often disappointing (24, 25). Poor weight loss and maintenance of weight
loss are, in part, due to the incompletely understood observation that some people lose weight more easily than
others, independent of compliance (23, 25, 129, 130).
Results presented here suggest that OW/OB individuals
who respond poorly to a weight loss program may be those
that have higher baseline chronic inﬂammation. Such
individuals may require a longer, or different, approach
than those that are less inﬂamed.
Poor compliance is also a major cause of low success rates
in weight loss management programs (24, 131, 132). This is
not surprising because these programs typically require
dietary and activity modiﬁcations that are difﬁcult for many
to initiate and sustain. It is suggested that weight management programs will be more successful if interventions,
such as that employed here, are used as a ﬁrst step to help
participants transition to healthier eating and lifestyle
habits. In this study, participants were not instructed to
make any lifestyle changes other than to eat 2 nutrient bars
each day. This study design imposed relatively minor
restrictions on participants, and compliance was very high
(95%). The modest but statistically signiﬁcant loss in
weight (1.1 6 0.5 kg; P = 0.0051) and waist circumference
(3.1 6 1.4 cm; P = 0.019) that occurred in the less inﬂamed
OW/OB subgroup may have been the result of barinduced improvement in metabolic health that enabled

The FASEB Journal x www.fasebj.org

MCCANN ET AL.

the metabolic ﬂexibility required to initiate weight loss.
Early success in weight management programs may encourage participants toward higher compliance throughout the program, and early identiﬁcation of participants
whose metabolism is resistant to change should also be
beneﬁcial.
Potential for use of natural food-based nutrient
mixtures as alternatives or companions to drugs used
to treat obesity-associated metabolic dysregulation
Obesity-associated metabolic dysregulation is often treated
with drugs: dyslipidemia with statins and ﬁbrates (133,
134), insulin resistance with thiazolidinediones and metformin (135, 136), and chronic inﬂammation with nonsteroidal anti-inﬂammatory drugs (137). All of these drugs
have demonstrated clinical beneﬁts. However, because
most drugs act by pharmacologically blocking or accelerating cellular pathways, pleiotropic, often poorly understood and sometimes negative side effects can result
(134, 138, 139). On the other hand, food-based nutrient
mixtures, such as the nutrient bar used here, that contain
nutrients at normal dietary concentrations are not expected to have signiﬁcant negative side effects. The full potential of such food-based nutrient mixtures as alternatives
or companions to drugs for treatment of metabolic dysregulation associated with obesity has not been given adequate attention.
Limitations
The clinical trial design used in this and previous (51)
nutrient bar trials did not include a placebo control
group; instead, participants acted as their own controls.
Difﬁculties in applying the same placebo standards used
for drug trials to nutritional interventions have been
widely discussed [e.g., (140)]. In addition, dietary intake
during the trial was not monitored. Thus, it is not known
whether participants altered their food choices or consumed fewer calories during the trials. If such changes
occurred, they could have contributed to the positive
effects observed.

CONCLUSIONS
The broad-spectrum metabolic and anthropometric improvements observed after 2 months of twice-daily consumption of a low-calorie food-based nutrient bar aimed at
ﬁlling gaps in poor diets suggest that it is not necessary to
impose severe changes in diet and lifestyle patterns to begin to effect positive changes in the OW/OB, and also in
the lean. Two-month consumption of the nutrient bar did
not make the OW/OB lean or completely correct unhealthy metabolism, but it did begin a process of favorable
metabolic change. The fact that almost all statistically
signiﬁcant favorable changes occurred in the subgroup
of the OW/OB with less chronic inﬂammation suggests
an explanation for why some OW/OB have difﬁculty
losing weight. This study highlights the power of foodbased, targeted, dietary interventions as alternatives or
NUTRIENT BAR IMPROVES METABOLISM AND WEIGHT LOSS

adjuncts to the use of drugs to treat obesity and associated
metabolic dysregulation.
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Gomez-Zumaquero, J. M., Clemente-Postigo, M., Estruch, R.,
Cardona Diaz, F., Andrés-Lacueva, C., and Tinahones, F. J. (2012)
Inﬂuence of red wine polyphenols and ethanol on the gut
microbiota ecology and biochemical biomarkers. Am. J. Clin. Nutr.
95, 1323–1334
49. Van Duynhoven, J., Vaughan, E. E., van Dorsten, F.,
Gomez-Roldan, V., de Vos, R., Vervoort, J., van der Hooft, J. J.,
Roger, L., Draijer, R., and Jacobs, D. M. (2013) Interactions of
black tea polyphenols with human gut microbiota: implications
for gut and cardiovascular health. Am. J. Clin. Nutr. 98(6, Suppl)
1631S–1641S

The FASEB Journal x www.fasebj.org

MCCANN ET AL.

50. Kris-Etherton, P. M., Harris, W. S., and Appel, L. J.; Nutrition
Committee. (2003) Fish consumption, ﬁsh oil, omega-3 fatty acids,
and cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 23,
e20–e30
51. Mietus-Snyder, M. L., Shigenaga, M. K., Suh, J. H., Shenvi, S. V., Lal,
A., McHugh, T., Olson, D., Lilienstein, J., Krauss, R. M.,
Gildengoren, G., McCann, J. C., and Ames, B. N. (2012) A nutrientdense, high-ﬁber, fruit-based supplement bar increases HDL
cholesterol, particularly large HDL, lowers homocysteine, and raises
glutathione in a 2-wk trial. FASEB J. 26, 3515–3527
52. Asztalos, B. F., Cupples, L. A., Demissie, S., Horvath, K. V., Cox, C. E.,
Batista, M. C., and Schaefer, E. J. (2004) High-density lipoprotein
subpopulation proﬁle and coronary heart disease prevalence in
male participants of the Framingham Offspring Study. Arterioscler.
Thromb. Vasc. Biol. 24, 2181–2187
53. Musunuru, K., Orho-Melander, M., Caulﬁeld, M. P., Li, S., Salameh,
W. A., Reitz, R. E., Berglund, G., Hedblad, B., Engström, G.,
Williams, P. T., Kathiresan, S., Melander, O., and Krauss, R. M.
(2009) Ion mobility analysis of lipoprotein subfractions identiﬁes
three independent axes of cardiovascular risk. Arterioscler. Thromb.
Vasc. Biol. 29, 1975–1980
54. Hellerstein, M., and Turner, S. (2014) Reverse cholesterol
transport ﬂuxes. Curr. Opin. Lipidol. 25, 40–47
55. Novotný, D., Vaverková, H., and Karásek, D. (2012) Adiponectin:
a perspective adipose tissue marker with antiinﬂammatory and
antiaterogenic potencial. In Lipoproteins: Role in Health and Disease,
pp. 677–700, InTech, Rijeka, Croatia
56. Uhlar, C. M., and Whitehead, A. S. (1999) Serum amyloid A, the
major vertebrate acute-phase reactant. Eur. J. Biochem. 265, 501–523
57. Maki, K. C., Carson, M. L., Kerr Anderson, W. H., Geohas, J., Reeves,
M. S., Farmer, M. V., Turowski, M., Miller, M., Kaden, V. N., Dicklin,
M. R., and Rains, T. M. (2009) Lipid-altering effects of different
formulations of hydroxypropylmethylcellulose. J. Clin. Lipidol. 3,
159–166
58. U.S. Department of Agriculture, Agricultural Research Service.
(2011) USDA National Nutrient Database for Standard Reference, Release 24. Nutrient Data Laboratory Home Page. Available at: http://www.ars.usda.gov/ba/bhnrc/ndl. Accessed March
27, 2015
59. U.S. Department of Agriculture, National Agricultural Library.
(2007) USDA Database for the Flavonoid Content of Selected
Foods, Release 2.1. Available at: http://www.nal.usda.gov/fnic/
foodcom/Data/Flav/Flav02-1.pdf. Accessed October 9, 2014.
60. Myers, G. L., Rifai, N., Tracy, R. P., Roberts, W. L., Alexander, R. W.,
Biasucci, L. M., Catravas, J. D., Cole, T. G., Cooper, G. R., Khan,
B. V., Kimberly, M. M., Stein, E. A., Taubert, K. A., Warnick, G. R.,
and Waymack, P. P.; CDC; AHA. (2004) CDC/AHA workshop on
markers of inﬂammation and cardiovascular disease: application to
clinical and public health practice: report from the laboratory science discussion group. Circulation 110, e545–e549
61. Friedewald, W. T., Levy, R. I., and Fredrickson, D. S. (1972)
Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin.
Chem. 18, 499–502
62. Caulﬁeld, M. P., Li, S., Lee, G., Blanche, P. J., Salameh, W. A.,
Benner, W. H., Reitz, R. E., and Krauss, R. M. (2008) Direct
determination of lipoprotein particle sizes and concentrations by
ion mobility analysis. Clin. Chem. 54, 1307–1316
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Bernard, M., Chapman, M. J., and Turpin, G. (2001) Elevated Creactive protein constitutes an independent predictor of advanced
carotid plaques in dyslipidemic subjects. Arterioscler. Thromb. Vasc.
Biol. 21, 1962–1968
75. St-Onge, M. P., Zhang, S., Darnell, B., and Allison, D. B. (2009)
Baseline serum C-reactive protein is associated with lipid
responses to low-fat and high-polyunsaturated fat diets. J. Nutr.
139, 680–683
76. Desroches, S., Archer, W. R., Paradis, M. E., Dériaz, O., Couture, P.,
Bergeron, J., Bergeron, N., and Lamarche, B. (2006) Baseline
plasma C-reactive protein concentrations inﬂuence lipid and lipoprotein responses to low-fat and high monounsaturated fatty acid
diets in healthy men. J. Nutr. 136, 1005–1011
77. Erlinger, T. P., Miller III, E. R., Charleston, J., and Appel, L. J. (2003)
Inﬂammation modiﬁes the effects of a reduced-fat low-cholesterol
diet on lipids: results from the DASH-sodium trial. Circulation 108,
150–154
78. Hilpert, K. F., Kris-Etherton, P. M., and West, S. G. (2005) Lipid
response to a low-fat diet with or without soy is modiﬁed by Creactive protein status in moderately hypercholesterolemic adults.
J. Nutr. 135, 1075–1079
79. Gigleux, I., Jenkins, D. J., Kendall, C. W., Marchie, A., Faulkner,
D. A., Wong, J. M., de Souza, R., Emam, A., Parker, T. L., Trautwein,
E. A., Lapsley, K. G., Connelly, P. W., and Lamarche, B. (2007)
Comparison of a dietary portfolio diet of cholesterol-lowering
foods and a statin on LDL particle size phenotype in hypercholesterolaemic participants. Br. J. Nutr. 98, 1229–1236
80. Kong, L. C., Wuillemin, P. H., Bastard, J. P., Sokolovska, N., Gougis,
S., Fellahi, S., Darakhshan, F., Bonnefont-Rousselot, D., Bittar, R.,
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